Who Benefits Most from Psychedelic-Assisted Therapy? New Study Reveals Key Traits
Psychedelic-assisted therapy is gaining attention as a potential treatment for mental health disorders. Using substances like psilocybin and LSD within a controlled setting, this approach shows promise—but results vary widely. Researchers at Charité – Universitätsmedizin Berlin have now identified the type of patient most likely to benefit from it for the first time. The therapy involves carefully guided sessions where patients take psychedelics in a structured environment. Success depends on thorough preparation, professional supervision during the experience, and follow-up support to integrate the insights gained. Charité’s study highlights that not all patients respond the same way.
Patients with a stable social network, strong family or partner support, and an openness to new experiences tend to see better outcomes. Secure attachment styles and certain personality traits—such as avoidant, dependent, or obsessive-compulsive tendencies—may also respond well. However, those with paranoid, schizoid, or schizotypal traits require extra caution. The Charité warns against mixing psychedelics with other substances like cocaine, amphetamines, alcohol, or cannabis, as these can interfere with the therapy’s effectiveness. They strongly advise that treatment should only take place in specialised centres, preferably within clinical trials.
The findings provide clearer guidance on who might benefit most from psychedelic-assisted therapy. While the approach holds potential, its success relies on strict professional oversight and tailored patient selection. Charité’s recommendations aim to ensure safer and more effective use of this emerging treatment.
